基准医疗UriFind 助力尿路上皮癌术前无创诊断及术后复发监测

Group 1 - The 2025 Guangdong Urology Academic Conference and Bladder Cancer Academic Conference successfully concluded in Shenzhen, showcasing the innovative UriFind product from Benchmark Medical [1] - The clinical research involving 1,172 samples demonstrated that the UriFind kit has a sensitivity of 89.74%, specificity of 92.46%, and accuracy of 91.47% for the auxiliary diagnosis of urothelial carcinoma [1] - UriFind shows significant advantages in detecting early, small, residual, and recurrent bladder cancer, providing strong evidence for early screening and diagnosis [1] Group 2 - Benchmark Medical, a subsidiary of Kangsheng Global Medical Testing Group, focuses on cancer early diagnosis and screening using tumor DNA methylation sequencing technology [5] - The company develops products covering over 70% of high-incidence cancers, including lung, breast, digestive system, and urinary system cancers, throughout the entire process of early screening, diagnosis, recurrence monitoring, and companion diagnosis [5] - Benchmark Medical has also created a big data and artificial intelligence platform centered on early screening, diagnosis, and treatment of lung cancer [5]